Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q1 FY26 Earnings Presentation
19 slides from Gland Pharma's earnings presentation, Aug 5, 2025
Slide 1: Investor Presentation Q1FY26
GLAND PHARMA Investor Presentation Q1FY26 05 August 2025
Slide 2: Safe Harbour Statement
Safe Harbour Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendatio
Slide 3: Financial Highlights
in Financial Highlights
Slide 4: Consolidated P&L Highlights
Consolidated P&L Highlights ₹ Mn Particulars Q1 FY26 Q1 FY25 YoY Q4 FY25 QoQ Revenue from operations 15,056 14,017 7% 14,249 6% Other Income 575 514 12% 440 31% Total Income 15,631 14,531 8% 14,689 6% Gross Profit(1) 9,845 8,375 18% 9,370 5% Gross Profit margin (%) 65% 60% 66% EBITDA(2) 3,678 2,654
Slide 5: Consolidated Financial Highlights
Consolidated Financial Highlights Revenue from Operations Gross Profit (1) / Gross Profit Margin (2) (₹ Mn) (₹ Mn / %) 15,056 14,017 14,249 9,845 9,370 8,375 60% 66% 65% Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 EBITDA (3) / EBITDA Margin (4) PAT / PAT Margin (5) (₹ Mn / %) (₹ Mn / %) 3,475 3,
Slide 6: Base Business (Gland) P&L Highlights
Base Business (Gland) P&L Highlights ₹ Mn Particulars Q1 FY26 Q1 FY25 YoY Q4 FY25 QoQ Revenue from operations 10,409 10,134 3% 10,332 1% Other Income 556 493 13% 436 28% Total Income 10,965 10,626 3% 10,768 2% Gross Profit(1) 6,144 5,348 15% 6,280 -2% Gross Profit margin (%) 59% 53% 61% EBITDA(2) 3,
Slide 7: Base Business (Gland) Financial Highlights
Base Business (Gland) Financial Highlights Revenue from Operations Gross Profit (1) / Gross Profit Margin (2) (₹ Mn) (₹ Mn / %) 10,134 10,332 10,409 6,280 6,144 5,348 61% 59% 53% Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 EBITDA / EBITDA Margin (3) / PAT / PAT Margin (4) R&D Expenses (₹ Mn / %)
Slide 8: Group Financial Highlights (1/2)
Group Financial Highlights (1/2) Net Worth (1) ROCE (2) / RONW (3) (₹ Mn) (%) RoCE RoNW 87,238 91,507 95,587 11% 15.00% 11% 9% 10.00% 9% 9% 8% 5.00% 0.00% FY24 FY25 Jun'25 FY24 FY25 Jun'25 Capital Expenditure Asset Turnover Ratio (4)(5) (₹ Mn) (x) 886 786 1.5 1.4 1.5 637 0.6 0.5 0.5 Q1 FY25 Q4 FY25
Slide 9: Group Financial Highlights (2/2)
Group Financial Highlights (2/2) Cash and Bank Balances / Net Cash (1) Cash Flow from Operations (₹ Mn) Total Cash (₹ Mn) Net Cash 4,277 25,562 26,179 3,259 22,870 23,009 2,620 18,394 15,197 Q1 FY25 Q4 FY25 Q1 FY26 FY24 FY25 Jun'25 Net Working Capital (2) Cash Conversion Cycle (CCC) (3)(4) (₹ Mn) (#
Slide 10: Business Update
in Business Update
Slide 11: Base Business (Gland) Updates
Base Business (Gland) Updates • R&D Expenses: Total R&D expenses were ₹460 million in Q1 FY26, representing 4.4% of revenue. • New Launches: The company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (three new strengths), Liraglutide, and Acetamino
Slide 12: Cenexi Updates
Cenexi Updates Q1 FY26 Q1 FY25 Q4 FY25 Particulars YoY QoQ € Mn. ₹ Mn. € Mn. ₹ Mn. € Mn. ₹ Mn. Revenue from operations 48 4,648 43 3,883 20% 43 3,917 19% Gross Margin 38 3,701 34 3,026 22% 34 3,089 20% % margin 80% 80% 78% 78% 79% 79% EBITDA 0.9 86 (3) (286) (5) (479) % margin 2% 2% -7% -7% -12% -12
Slide 13: Geographical Revenue
SS Geographical — Revenue |
Slide 14: US Market
US Market ₹ Mn Group Revenue Contribution Gland Cenexi -2% YoY -5% YoY 163% YoY 7,524 7,714 7,170 7,628 7,918 7,443 273 204 104 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 US Filings Update US Contribution to the Group New Launches (3) Q1FY26 Cumulative • The company laun
Slide 15: Europe Market
Europe Market ₹ Mn Group Revenue Contribution Gland Cenexi 29% YoY 57% YoY 23% YoY 639 3,302 2,663 2,801 2,159 2,399 2,566 407 402 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Europe Contribution to the Group Business Update • Gland: Launched 3 new molecules, including Col
Slide 16: Other Core Markets (Canada, Australia and New Zealand)
Other Core Markets (Canada, Australia and New Zealand) ₹ Mn Group Revenue Contribution Gland Cenexi 65% YoY 144% YoY 5% YoY 739 437 473 601 253 266 447 164 194 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Other Core Markets Contribution to the Group Business Update 5% • Li
Slide 17: Rest of the World
Rest of the World ₹ Mn Group Revenue Contribution Gland Cenexi 5% YoY 3% YoY 6% YoY 1,481 1,533 2,849 2,978 1,254 2,404 1,368 1,445 1,150 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 RoW Contribution to the Group Business Update • Q1FY26 revenue increased by 3% 20% compare
Slide 18: India
India ₹ Mn Gland India Contribution to the Group Business Update 13% YoY 4% • Q1FY26 revenue increased by 13% over 594 Q1FY25, driven by volume growth in 527 525 FY25 existing products, including Huminsulin. Q1 FY25 Q4 FY25 Q1 FY26 18
Slide 19: Thank You
GLAND PHARMA Thank You Corporate Office Investor Relations: Gland Pharma Limited Sampath Kumar Pallerlamudi Plot No. 11 & 84, TSIIC Phase: IV Company Secretary & Compliance Officer Pashamylaram (V), Patancheru (M), Sangareddy District Shriniwas P. Dange Hyderabad 502307, Telangana, India Investor Re